NMR of heparin API: Investigation of unidentified signals in the USP-specified range of 2.12-3.00 ppm

Analytical and Bioanalytical Chemistry

Volumn 399, Issue 2, 2011, Pages 651-662

  Lee, Sarah E ^a   Chess, Edward K ^a   Rabinow, Barrett ^a   Ray, G Joseph ^a   Szabo, Christina M ^a   Melnick, Bennett ^a   Miller, Reagan L ^a   Nair, Lakshmy M ^a   Moore, Edwin G ^a  

^a BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

Acetylation; Heparin; Isotopic labeling; NMR

Indexed keywords

ACTIVE PHARMACEUTICAL INGREDIENTS; CHEMICAL MOIETIES; CHEMICAL SPECIES; CHEMICAL TREATMENTS; CHONDROITIN SULFATES; HEADSPACE GAS CHROMATOGRAPHY/MASS SPECTROMETRIES; HEPARIN; ISOTOPIC LABELING; NMR; NMR ANALYSIS; NMR DIFFUSION; NMR SIGNALS; O-ACETYLATION; QUANTITATIVE METHOD; SPIKING STUDY; UNITED STATES PHARMACOPEIAS;

ACETYLATION; DRUG PRODUCTS; EXPERIMENTS; GAS CHROMATOGRAPHY; ION CHROMATOGRAPHY; ISOTOPES; POLYSACCHARIDES; RESONANCE;

NUCLEAR MAGNETIC RESONANCE;

ANTICOAGULANT AGENT; CHONDROITIN SULFATE; HEPARIN; NITROUS ACID;

ACETYLATION; ARTICLE; CHEMISTRY; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POLYMERIZATION;

ACETYLATION; ANTICOAGULANTS; CHONDROITIN SULFATES; HEPARIN; MAGNETIC RESONANCE SPECTROSCOPY; NITROUS ACID; POLYMERIZATION;

EID: 79251628029     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-010-4262-y     Document Type: Article

References (24)

1. I Capila RJ Linhardt 2002 Heparin-protein interactions Angew Chem Int Ed Engl 41 391 412 10.1002/1521-3773(20020201)41:3<390::AID-ANIE390>3.0.CO;2- B
2. RJ Linhardt 1991 Heparin: an important drug enters its seventh decade Chem Ind 2 45 50
3. Linhardt RJ, Toida T (1997) Carbohydrates in drug design. Marcel Dekker, New York, pp 277-341
4. B Casu 1990 Heparin structure Haemostasis 20 62 73 1:CAS:528: DyaK3MXisVartL0%3D
5. AK Korrir CK Larive 2007 On-line NMR detection of microgram quantities of heparin-derived oligosaccharides and their structure elucidation by microcoil NMR Anal Bioanal Chem 388 1707 1716 10.1007/s00216-007-1400-2
6. AK Korrir CK Larive 2009 Advances in the separation, sensitive detection, and characterization of heparin and heparin sulfate Anal Bioanal Chem 393 155 169 10.1007/s00216-008-2412-2
7. M Guerrini D Besccati Z Schriver A Naggi K Viswanathan A Bisio I Capila JC Lansing S Guglieri B Fraser A Al-Hakim NS Gunay Z Zhang L Robinson L Buhse M Nasr J Woodcock R Langer G Venkataraman RJ Linhardt B Casu G Torri R Sasisekharan 2008 Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events Nat Biotechnol 26 669 675 1:CAS:528:DC%2BD1cXmvVCisrY%3D 10.1038/nbt1407
8. TK Kishimoto K Viswanathan T Ganguly S Elankumaran S Smith K Pelzer JC Lansing N Sriranganathan G Zhao Z Galcheva-Gargova A Al-Hakim GS Bailey B Fraser S Roy T Rogers-Cotrone L Buhse M Whary J Fox M Nasr GJ Dal Pan Z Shriver RS Langer G Venkataraman KF Austen J Woodcock R Sasisekharan 2008 Contaminated heparin associated with adverse clinical events and activation of the contact system N Engl J Med 358 2457 2467 1:CAS:528:DC%2BD1cXmvFKmtb4%3D 10.1056/NEJMoa0803200
9. ML Trehy JC Reepmeyer RE Kolinski BJ Westenberger LF Buhsee 2009 Analysis of heparin sodium by SAX/HPLC for contaminants and impurities J Pharm Biomed Anal 49 670 673 1:CAS:528:DC%2BD1MXivVGjtr8%3D 10.1016/j.jpba.2008.12.013
10. C Viskov E Bouley P Hubert C Martinez F Herman W Jeske D Hoppensteadt JM Walenga J Fareed 2009 Isolation and characterization of contaminants in recalled unfractionated heparin and low-molecular-weight heparin Clin Appl Thromb Hemost 15 395 401 1:CAS:528:DC%2BD1MXhtValu7vE 10.1177/1076029609338710
11. J McKee S Bairstow C Szabo J Ray T Wielgos P Hu E Chess M Nordhaus T Hai J Campbell S Donovan N Riedel J Cammack R Johnson N Viseux 2010 Structure elucidation and biological activity of the oversulfated chondroitin sulfate contaminant in Baxter heparin J Clin Pharmacol 50 1159 1170 10.1177/ 0091270009355158 1:CAS:528:DC%2BC3cXhtlSgsr7I 10.1177/0091270009355158
12. Food and Drug Administration (2008) Information on heparin sodium injection. http://www.fda.gov/cder/drug/infopage/heparin/default.htm#screening
13. USP Proposed Interim Revision Announcement on Heparin Sodium [Mar.-Apr. 2009]. Pharmacopeial Forum, vol 35(2)
14. USP Interim Revision Announcement on Heparin Sodium [Sept.-Oct. 2009]. Pharmacopeial Forum, vol 35(5)
15. CD Hurd MP Puterbaugh 1930 Concentration of hydrogen peroxide solutions J Am Chem Soc 52 950 953 1:CAS:528:DyaA3cXit1Khsg%3D%3D 10.1021/ja01366a016
16. FP Greenspan 1946 Convenient preparation of per-acids J Am Chem Soc 68 907 1:CAS:528:DyaH28XitVKksA%3D%3D 10.1021/ja01209a502
17. Conrad HE (1995) Nitrous acid degradation of glycosaminoglycans. Curr Protoc Mol Biol Chapter 17:Unit17.22.1-17.22.5.
18. LM Sayre 1986 Metal ion catalysis of amide hydrolysis J Am Chem Soc 108 1632 1635 1:CAS:528:DyaL28XhsVyjsLo%3D 10.1021/ja00267a037
19. HL Vaughn MD Robbins 1975 A rapid procedure for the hydrolysis of amides to acids J Org Chem 40 1187 1189 1:CAS:528:DyaE2MXlvFWqurw%3D 10.1021/jo00896a050
20. H Liu Z Zhang RJ Linhardt 2009 Lessons learned from the contamination of heparin Nat Prod Rep 26 313 321 1:CAS:528:DC%2BD1MXisVGjsL8%3D 10.1039/b819896a
21. RJ Linhardt NS Gunay 1999 Production and chemical processing of low molecular weight heparins Semin Thromb Hemost 25 5 16 1:CAS:528: DyaK1MXntlart74%3D 10.1055/s-2007-996417
22. 13C nuclear magnetic resonance spectroscopy for characterization of heparin preparations Semin Thromb Hemost 27 473 482 1:CAS:528: DC%2BD3MXosVSnsr8%3D 10.1055/s-2001-17958
23. E Santaniello P Ferraboschi P Sozzani 1981 Reduction of esters to alcohols by means of sodium borohydride in polyethylene glycols J Org Chem 46 4584 4585 1:CAS:528:DyaL3MXls1ylur8%3D 10.1021/jo00335a058
24. L-C Li J-X Jiang J Ren Y Ren CU Pittman Jr H-J Zhu 2006 Unexpected selectivity in sodium borohydride reductions of α-substituted esters: experimental and theoretical studies Eur J Org Chem 2006 1981 1990 10.1002/ejoc.200500824